Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
for Advanced Endometrial Carcinoma
Drug: Bevacizumab
231 locations incl. Birmingham
Sponsor: National Cancer Institute (NCI)
Sex: Female·Age: 18+
Code: NCT07198074·Phase 3·Recruiting